AUS
NZ
UK
CA
USA
IND
Source: LookerStudio, Shutterstock
Summary
- Several pharmaceutical companies, such as Moderna, Pfizer-BioNTech, Astrazeneca, and others are expected to report huge revenues in FY 2021 as vaccination rollouts gain momentum across the world.
- Total sales of Moderna and Pfizer/BioNTech vaccines in 2021 is expected to be around US $18.4 billion and US $15 billion, respectively.
Major pharmaceutical companies such as Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE) Biontech SE’s (NASDAQ: BNTX), Astrazeneca (LON: AZN), and others are expected to report huge revenues in FY 2021 as vaccination rollouts are gaining momentum across the world.
While the Moderna and Pfizer-BioNTech vaccines cost between US$ 30 and US$ 40 for two doses, the Astrazeneca and the Johnson & Johnson shots are sold on a not-for-profit basis until the pandemic is under control.
Moderna
US-based pharmaceutical giant Moderna (NASDAQ: MRNA) estimates its total sales to be around US $18.4 billion in FY 2021. The UK bought 17 million doses of the vaccine while the EU bought 310 million, with an option to purchase an additional 150 million doses in FY 2022.
Moreover, the US placed an order of 300 million doses, while Japan purchased 50 million shots. The pharmaceutical company’s vaccine costs about US $30 for two required shots in the US and about US $36 in the EU.
Moderna’s (NASDAQ: MRNA) shares closed at US $132.19, down by 0.083 per cent as of 5 March and were down by 1.27 per cent in pre-market on 8 March 2021.
Copyright © 2021 Kalkine Media Pty Ltd.
Pfizer/BioNTech
US-based drugmaker Pfizer (NYSE: PFE) vaccine tied up with German pharma company BioNTech SE’s (NASDAQ:BNTX) and is expected to make total sales worth up to US $15 billion in FY 2021 based on current deals. However, revenues can go higher.
Its total orders are about 780 million doses, including 200 million doses for US worth US $3.9 billion and 300 million shots ordered by the EU. Another 40 million doses are included through the Covovax facility for lower-income countries. The vaccine costs US $39 for two doses in the US and approximately US $30 in the EU.
Want to know more? Do read: How effective is the Pfizer-BioNtech vaccine against the South African coronavirus strain?
Pfizer Inc’s (NYSE: PFE) stocks closed at US $34.39, up by 0.56 per cent as of 5 March and were up marginally in pre-market session on 8 March 2021, while Pfizer’s partner Biontech SE’s (NASDAQ:BNTX) stock prices closed at US $96.20 on 5 March and were down by 1.14 per cent in pre-market on 8 March 2021.
Johnson & Johnson
US-based multinational company Johnson & Johnson (NYSE:JNJ) vaccine is the first single dose vaccines to be developed for the novel coronavirus. The company expects sales to reach up to US $10 billion by delivering around 1 billion doses in FY 2021. The US has ordered 100 million shots, with an option to purchase up to 200 million more doses. It costs US $10 per dose.
Johnson & Johnson’s (NYSE:JNJ) share prices stood at US $56.10, on 5 March and were up by 0.65 per cent on 8 March 2021 in pre-market session.
Astrazeneca
UK-based drug manufacturer Astrazeneca (LON:AZN) and Oxford university jointly developed vaccine is expected to reach total sales of up to US $2 billion to US $3 billion in 2021, with analysts expecting FY 2021 sales to be around US $1.9 billion and FY 2022 sales at US $3 billion. The vaccine costs between US $4.30 and US $10 for two required doses, due to its commitment to sell vaccines at not-for-profit during the pandemic.
UK-listed drug manufacturer Astrazeneca (LON:AZN)’s stocks were trading at GBX 6,908.00, up by 0.73 per cent as of 8 March at 13:43 pm GMT+1.
